Search

Displaying results 251 - 260 of 2445 in total
  1. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  2. Drug

    Thonzylamine

    go.drugbank.com/drugs/DB11235
    Approved

    Thonzylamine is an antihistamine and anticholinergic drug. It is available as combination products with DB04837 or DB00388 for temporary relief of symptoms of common cold, hay fever (allergic rhinitis) or other upper respiratory allergies.

    Mixtures: Nasopen PE, Poly Hist PD
  3. Drug

    Obiltoxaximab

    go.drugbank.com/drugs/DB05336
    Approved

    Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody (mAb) that binds the PA component of B. anthracis toxin. It has an approximate molecular weight of 148 kDa.

  4. Drug

    AZD2389

    go.drugbank.com/drugs/DB22104
    Investigational

    [L54978] It is currently undergoing safety, tolerability, and PK/PD profiling in clinical trials (e.g.

  5. Drug

    Valine

    go.drugbank.com/drugs/DB00161
    ApprovedInvestigationalNutraceutical

    Valine is a branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.

    Mixtures: Aminosyn-PF, Aminosyn-PF
  6. Drug

    Sodium acetate

    go.drugbank.com/drugs/DB09395
    ApprovedInvestigational

    Sodium Acetate is chemically designated CH3COONa, a hygroscopic powder very soluble in water. Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in buffer solutions. Medically, sodium acet...

    Mixtures: Isolyte S pH 7.4, Isolyte P in Dextrose
  7. Drug

    Segesterone acetate

    go.drugbank.com/drugs/DB14583
    Approved

    Segesterone acetate is a steroidal progestin or synthetic progesterone and a 19-norprogesterone derivative with no CH3 group radical in position 6 . In animal studies, segesterone acetate was shown to be one of the most potent progestins...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Hydroxychloroquine

    go.drugbank.com/drugs/DB01611
    ApprovedInvestigational

    [L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546]

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  9. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion … This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

    Categories: Cytochrome P-450 CYP1A1 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Fluciclovine (18F)

    go.drugbank.com/drugs/DB13146
    ApprovedInvestigational

    Fluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. The structure of fluciclovine allows it to be uptaken by t...